Table 2.

Overview of biopsy confirmed CIN 2+ cases

Case #	Study group	FRE	ONC+RE	HPV	Viral load	Histology
A	GS	NEG	NEG	16	0.0429	CIN 3
B	GS	NEG	NEG	16	10.0861	CIN 2
C	GS	L-SIL	ASC-US	16	8.3974	CIN 3
D	GS	ASC-US	L-SIL	16*,39	1186.5076	CIN 3
E	GS	ASC-US	H-SIL	18*,31,33,58	71.6029	CIN 3
F	GS	NEG	NEG	39	0.7781	VIN 3
G	MS	H-SIL	ASC-US	31	0.5285	CIN 3
H	MS	NEG	NEG	31*,35	0.0144	CIN 2
I	MS	NEG	NEG	18	6.6268	CIN 3
J	NFR	NEG	NEG	16*,58	50.5446	CIN 3
K	NFR	NEG	ASC-H	16	26.6882	CIN 3
L	GS	NEG	NEG	16	0.3359	CIN 3
M	GS	NEG	L-SIL	16	13.6599	CIN 3
N	GS	NEG	ASC-R	16*,33	18.7129	CIN 3
O	GS	NEG	ASC-H	16	2.9539	CIN 2
P	GS	NEG	NEG	16	0.1970	CIN 2
Q	NFR	NEG	NEG	16,33*,53	186.7860	CIN 3

FRE = full manual rescreening without knowledge of quintile ranking or HPV status, ONC+RE = HR HPV targeted rescreening, e.g. with knowledge of oncogenic HPV type but without knowledge of the viral load

^*= only the viral load for the HPV type with the highest load is given. Viral load is expressed as HPV copies/cell.